S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
New Trump Bombshell (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Recession risks are fading, business economists say, but political tensions pose threat to economy
An Unusual Way to Invest in Gold (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
New Trump Bombshell (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Recession risks are fading, business economists say, but political tensions pose threat to economy
An Unusual Way to Invest in Gold (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
New Trump Bombshell (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Recession risks are fading, business economists say, but political tensions pose threat to economy
An Unusual Way to Invest in Gold (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
New Trump Bombshell (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Recession risks are fading, business economists say, but political tensions pose threat to economy
An Unusual Way to Invest in Gold (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000

Curis (CRIS) Stock Forecast & Price Target

$10.41
-0.24 (-2.25%)
(As of 02/9/2024 08:56 PM ET)

Curis Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

$37.33
258.63% Upside
High Forecast$60.00
Average Forecast$37.33
Low Forecast$26.00
TypeCurrent Forecast
2/12/23 to 2/12/24
1 Month Ago
1/13/23 to 1/13/24
3 Months Ago
11/14/22 to 11/14/23
1 Year Ago
2/12/22 to 2/12/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$37.33$68.67$90.00$190.00
Predicted Upside258.63% Upside620.08% Upside652.93% Upside616.29% Upside
Get Curis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.


CRIS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CRIS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Curis Stock vs. The Competition

TypeCurisMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside258.63% Upside1,118.21% Upside8.84% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/9/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$51.00 ➝ $26.00+144.13%
11/17/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$26.00+339.93%
9/7/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$60.00+487.08%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:37 AM ET.












CRIS Price Target - Frequently Asked Questions

What is Curis's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Curis stock is Buy based on the current 3 buy ratings for CRIS. The average twelve-month price prediction for Curis is $37.33 with a high price target of $60.00 and a low price target of $26.00. Learn more on CRIS's analyst rating history.

Do Wall Street analysts like Curis more than its competitors?

Analysts like Curis more than other Medical companies. The consensus rating for Curis is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how CRIS compares to other companies.

Does Curis's stock price have much upside?

According to analysts, Curis's stock has a predicted upside of 318.22% based on their 12-month stock forecasts.

What analysts cover Curis?

Curis has been rated by HC Wainwright, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:CRIS) was last updated on 2/12/2024 by MarketBeat.com Staff

My Account -